Chk1 knockdown confers radiosensitization in prostate cancer stem cells

Wang,Xiaobin; Ma,Zhikun; Xiao,Zheng; Liu,Hui; Dou,Zhongling; Feng,Xiaoshan; Shi,Haijun

doi:10.3892/or.2012.2068

Chk1 knockdown confers radiosensitization in prostate cancer stem cells

Authors:
- Xiaobin Wang
- Zhikun Ma
- Zheng Xiao
- Hui Liu
- Zhongling Dou
- Xiaoshan Feng
- Haijun Shi
View Affiliations

Affiliations: Department of Urology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang 471003, P.R. China, Department of Oncology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang 471003, P.R. China, Department of Neurosurgery, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang 471003, P.R. China
Published online on: October 1, 2012 https://doi.org/10.3892/or.2012.2068
Pages: 2247-2254

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Radioresistance is responsible for treatment failure after radiotherapy in localized prostate cancer, while prostate cancer stem cells promote radioresistance by preferential activation of the DNA damage response. Chk1 inhibition has been shown to sensitize many tumor cells to radiation. However, whether Chk1 inhibition can potentiate the cytotoxic effects of radiation on prostate cancer stem cells remains to be elucidated. In this study, CD133+CD44+ cells were isolated using microbeads and were found to possess cancer stem cell properties. Using shRNA, Chk1 was knocked down in the sorted CD133+CD44+ cells. Our results demonstrated that Chk1 knockdown abrogated the radiation-induced G2/M arrest, inhibited DNA damage repair and promoted premature mitosis, leading to increased apoptosis in the radiated sorted CD133+CD44+ cells. Moreover, these effects were accompanied by caspase-2 activation and the inactivation of phosphorylated Cdc25C and Cdc2. Our results suggest that Chk1 knockdown increases the radiosensitivity of CD133+CD44+ prostate cancer stem cells. Chk1 knockdown in prostate cancer stem cells may be an effective therapeutic strategy against prostate cancer.

View Figures

View References

1	Neppl-Huber C, Zappa M, Coebergh JW, et al: Changes in incidence, survival and mortality of prostate cancer in Europe and the United States in the PSA era: additional diagnoses and avoided deaths. Ann Oncol. 23:1325–1334. 2012. View Article : Google Scholar : PubMed/NCBI
2	Heidenreich A, Bellmunt J, Bolla M, et al: EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 59:61–71. 2011. View Article : Google Scholar : PubMed/NCBI
3	Bonkhoff H: Factors implicated in radiation therapy failure and radiosensitization of prostate cancer. Prostate Cancer. 2012:5932412012. View Article : Google Scholar : PubMed/NCBI
4	Beckendorf V, Guerif S, Le PE, et al: 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys. 80:1056–1063. 2011.PubMed/NCBI
5	Merry C, Fu K, Wang J, Yeh IJ and Zhang Y: Targeting the checkpoint kinase Chk1 in cancer therapy. Cell Cycle. 9:279–283. 2010. View Article : Google Scholar : PubMed/NCBI
6	Stracker TH, Usui T and Petrini JH: Taking the time to make important decisions: the checkpoint effector kinases Chk1 and Chk2 and the DNA damage response. DNA Repair. 8:1047–1054. 2009. View Article : Google Scholar : PubMed/NCBI
7	Jackson SP and Bartek J: The DNA-damage response in human biology and disease. Nature. 461:1071–1078. 2009. View Article : Google Scholar : PubMed/NCBI
8	Diehn M and Clarke MF: Cancer stem cells and radiotherapy: new insights into tumor radioresistance. J Natl Cancer Inst. 98:1755–1757. 2006. View Article : Google Scholar : PubMed/NCBI
9	Baumann M, Krause M and Hill R: Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer. 8:545–554. 2008. View Article : Google Scholar : PubMed/NCBI
10	Hittelman WN, Liao Y, Wang L and Milas L: Are cancer stem cells radioresistant. Future Oncol. 6:1563–1576. 2010. View Article : Google Scholar : PubMed/NCBI
11	Visvader JE and Lindeman GJ: Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 8:755–768. 2008. View Article : Google Scholar : PubMed/NCBI
12	Eyler CE and Rich JN: Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol. 26:2839–2845. 2008. View Article : Google Scholar : PubMed/NCBI
13	Wang G, Wang Z, Sarkar FH and Wei W: Targeting prostate cancer stem cells for cancer therapy. Discov Med. 13:135–142. 2012.PubMed/NCBI
14	Maitland NJ and Collins AT: Prostate cancer stem cells: a new target for therapy. J Clin Oncol. 26:2862–2870. 2008. View Article : Google Scholar
15	Wu J, Lai G, Wan F, et al: Knockdown of checkpoint kinase 1 is associated with the increased radiosensitivity of glioblastoma stem-like cells. Tohoku J Exp Med. 226:267–274. 2012. View Article : Google Scholar : PubMed/NCBI
16	Xiao Z, Liu Q, Zhao B, Wu J and Lei T: Hypoxia induces hemorrhagic transformation in pituitary adenomas via the HIF-1α signaling pathway. Oncol Rep. 26:1457–1464. 2011.PubMed/NCBI
17	Ma CX, Janetka JW and Piwnica-Worms H: Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol Med. 17:88–96. 2011. View Article : Google Scholar : PubMed/NCBI
18	Carrassa L and Damia G: Unleashing Chk1 in cancer therapy. Cell Cycle. 10:2121–2128. 2011. View Article : Google Scholar : PubMed/NCBI
19	Chen Y and Sanchez Y: Chk1 in the DNA damage response: conserved roles from yeasts to mammals. DNA Repair. 3:1025–1032. 2004. View Article : Google Scholar : PubMed/NCBI
20	Lang SH, Frame FM and Collins AT: Prostate cancer stem cells. J Pathol. 217:299–306. 2009. View Article : Google Scholar : PubMed/NCBI
21	Collins AT, Berry PA, Hyde C, Stower MJ and Maitland NJ: Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 65:10946–10951. 2005. View Article : Google Scholar : PubMed/NCBI
22	Li C, Heidt DG, Dalerba P, et al: Identification of pancreatic cancer stem cells. Cancer Res. 67:1030–1037. 2007. View Article : Google Scholar : PubMed/NCBI
23	Tang DG, Patrawala L, Calhoun T, et al: Prostate cancer stem/progenitor cells: identification, characterization, and implications. Mol Carcinog. 46:1–14. 2007. View Article : Google Scholar : PubMed/NCBI
24	Wei C, Guomin W, Yujun L and Ruizhe Q: Cancer stem-like cells in human prostate carcinoma cells DU145: the seeds of the cell line. Cancer Biol Ther. 6:763–768. 2007. View Article : Google Scholar : PubMed/NCBI
25	Syljuasen RG, Sorensen CS, Hansen LT, et al: Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage. Mol Cell Biol. 25:3553–3562. 2005. View Article : Google Scholar : PubMed/NCBI
26	Binder A and Bohm L: Influence of irradiation and pentoxifylline on histone H3 phosphorylation in human tumour cell lines. Cell Prolif. 35:37–47. 2002. View Article : Google Scholar : PubMed/NCBI
27	Sorensen CS, Hansen LT, Dziegielewski J, et al: The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat Cell Biol. 7:195–201. 2005. View Article : Google Scholar : PubMed/NCBI
28	Bahassi EM, Ovesen JL, Riesenberg AL, Bernstein WZ, Hasty PE and Stambrook PJ: The checkpoint kinases Chk1 and Chk2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage. Oncogene. 27:3977–3985. 2008. View Article : Google Scholar : PubMed/NCBI
29	Xiao Z, Chen Z, Gunasekera AH, et al: Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents. J Biol Chem. 278:21767–21773. 2003. View Article : Google Scholar : PubMed/NCBI
30	Sanchez Y, Wong C, Thoma RS, et al: Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science. 277:1497–1501. 1997. View Article : Google Scholar : PubMed/NCBI
31	Sorensen CS, Melixetian M, Klein DK and Helin K: NEK11: linking CHK1 and CDC25A in DNA damage checkpoint signaling. Cell Cycle. 9:450–455. 2010. View Article : Google Scholar : PubMed/NCBI
32	Sidi S, Sanda T, Kennedy RD, et al: Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, Bcl-2, and caspase-3. Cell. 133:864–877. 2008. View Article : Google Scholar : PubMed/NCBI
33	Dumont F, Altmeyer A and Bischoff P: Radiosensitising agents for the radiotherapy of cancer: novel molecularly targeted approaches. Expert Opin Ther Pat. 19:775–799. 2009. View Article : Google Scholar : PubMed/NCBI
34	Yang H, Yoon SJ, Jin J, et al: Inhibition of checkpoint kinase 1 sensitizes lung cancer brain metastases to radiotherapy. Biochem Biophys Res Commun. 406:53–58. 2011. View Article : Google Scholar : PubMed/NCBI
35	Meuth M: Chk1 suppressed cell death. Cell Div. 5:212010. View Article : Google Scholar
36	Smith J, Tho LM, Xu N and Gillespie DA: The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res. 108:73–112. 2010. View Article : Google Scholar : PubMed/NCBI
37	Gao Q, Zhou J, Huang X, et al: Selective targeting of checkpoint kinase 1 in tumor cells with a novel potent oncolytic adenovirus. Mol Ther. 13:928–937. 2006. View Article : Google Scholar : PubMed/NCBI
38	Freytag SO, Stricker H, Pegg J, et al: Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res. 63:7497–7506. 2003.
39	Geoerger B, van Beusechem VW, Opolon P, et al: Expression of p53, or targeting towards EGFR, enhances the oncolytic potency of conditionally replicative adenovirus against neuroblastoma. J Gene Med. 7:584–594. 2005. View Article : Google Scholar
40	Tsuruta Y, Pereboeva L, Breidenbach M, et al: A fiber-modified mesothelin promoter-based conditionally replicating adenovirus for treatment of ovarian cancer. Clin Cancer Res. 14:3582–3588. 2008. View Article : Google Scholar